Lampasona V, Franciotta D, Furlan R, Zanaboni S, Fazio R, Bonifacio E, Comi G, Martino G
Department of Clinical Chemistry, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy.
Neurology. 2004 Jun 8;62(11):2092-4. doi: 10.1212/01.wnl.0000127615.15768.ae.
The authors used a liquid-phase radiobinding assay to measure serum anti-myelin oligodendrocyte protein (MOG) immunoglobulin (Ig) G in 87 patients with multiple sclerosis (MS), in 12 patients with encephalomyelitis, and in 47 healthy subjects. Anti-MOG IgM was determined in samples obtained at onset from 40 of 87 patients with MS and in control subjects. The frequency of positive samples with low titers of anti-MOG IgG (< or =5.7%) and IgM (< or =8.3%) was similar in all the groups and subgroups. Binding competition experiments showed that these antibodies had low affinity. Anti-MOG antibodies are not disease specific.
作者采用液相放射结合分析法,对87例多发性硬化症(MS)患者、12例脑脊髓炎患者及47名健康受试者的血清抗髓鞘少突胶质细胞糖蛋白(MOG)免疫球蛋白(Ig)G进行了检测。对87例MS患者中的40例患者起病时采集的样本及对照受试者样本测定了抗MOG IgM。抗MOG IgG低滴度(≤5.7%)和IgM低滴度(≤8.3%)的阳性样本在所有组和亚组中的频率相似。结合竞争实验表明,这些抗体亲和力较低。抗MOG抗体并非疾病特异性抗体。